ATE315231T1 - Verfahren zur feststellung der anwesenheit mutierten brca proteins - Google Patents

Verfahren zur feststellung der anwesenheit mutierten brca proteins

Info

Publication number
ATE315231T1
ATE315231T1 AT98910509T AT98910509T ATE315231T1 AT E315231 T1 ATE315231 T1 AT E315231T1 AT 98910509 T AT98910509 T AT 98910509T AT 98910509 T AT98910509 T AT 98910509T AT E315231 T1 ATE315231 T1 AT E315231T1
Authority
AT
Austria
Prior art keywords
determining
relates
protein
proteins
mutated brca
Prior art date
Application number
AT98910509T
Other languages
English (en)
Inventor
Lorrie A Adams
Timothy J Byrne
Gabriel M Cohn
Margaret T Reece
Original Assignee
Baystate Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baystate Medical Ct filed Critical Baystate Medical Ct
Application granted granted Critical
Publication of ATE315231T1 publication Critical patent/ATE315231T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT98910509T 1997-03-24 1998-03-23 Verfahren zur feststellung der anwesenheit mutierten brca proteins ATE315231T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4233797P 1997-03-24 1997-03-24

Publications (1)

Publication Number Publication Date
ATE315231T1 true ATE315231T1 (de) 2006-02-15

Family

ID=21921326

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910509T ATE315231T1 (de) 1997-03-24 1998-03-23 Verfahren zur feststellung der anwesenheit mutierten brca proteins

Country Status (7)

Country Link
US (1) US5965377A (de)
EP (1) EP0975973B1 (de)
AT (1) ATE315231T1 (de)
AU (1) AU6473598A (de)
CA (1) CA2284817C (de)
DE (1) DE69833105D1 (de)
WO (1) WO1998043092A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
AU7701100A (en) * 1999-09-03 2001-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
KR100468466B1 (ko) * 2001-08-25 2005-01-27 주식회사 랩 지노믹스 유방암 및 난소암 진단에 유용한 ｂｒｃａ１, ｂｒｃａ２유전자 돌연변이 및 이를 이용한 검색 방법
US7955288B2 (en) 2002-12-11 2011-06-07 Ferrosan Medical Devices A/S Gelatine-based materials as swabs
CA2716872C (en) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
WO2012071096A2 (en) 2010-09-03 2012-05-31 The Johns Hopkins University Arid1a and ppp2r1a mutations in cancer
CN104159527B (zh) 2012-03-06 2017-04-12 弗罗桑医疗设备公司 包含止血糊剂的压力容器
ES2672727T3 (es) 2012-05-25 2018-06-15 Laboratoire Hra Pharma Acetato de ulipristal para la prevención y el tratamiento de tumores de mama
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
JP6390873B2 (ja) 2013-06-21 2018-09-19 フェッローサン メディカル ディバイス エー／エス 減圧膨張させた乾燥組成物およびそれを保持するためのシリンジ
BR112016013322B1 (pt) 2013-12-11 2020-07-21 Ferrosan Medical Devices A/S métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit
BR112017007466B1 (pt) 2014-10-13 2021-03-02 Ferrosan Medical Devices A/S método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
CA2986981A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
CN110997944A (zh) * 2017-05-26 2020-04-10 生命科技股份有限公司 用于检测brca1/2中的大片段重排方法和系统
USRE50319E1 (en) 2017-10-16 2025-03-04 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
EP4321182A3 (de) 2018-05-09 2024-05-29 Ferrosan Medical Devices A/S Verfahren zur herstellung einer hämostatischen zusammensetzung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283190A (en) * 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
US5252458A (en) * 1990-12-31 1993-10-12 Symex Corp. Method for visually detecting the presence of a virus in a clinical specimen
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
ATE201445T1 (de) * 1994-08-12 2001-06-15 Myriad Genetics Inc Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens
ATE198623T1 (de) * 1994-08-12 2001-01-15 Myriad Genetics Inc Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
US5645995A (en) * 1996-04-12 1997-07-08 Baylor College Of Medicine Methods for diagnosing an increased risk for breast or ovarian cancer
US5905026A (en) * 1996-08-27 1999-05-18 Cornell Research Foundation, Inc. Method of detecting expression of and isolating the protein encoded by the BRCA1 gene

Also Published As

Publication number Publication date
CA2284817C (en) 2003-08-19
US5965377A (en) 1999-10-12
AU6473598A (en) 1998-10-20
WO1998043092A1 (en) 1998-10-01
EP0975973B1 (de) 2006-01-04
DE69833105D1 (de) 2006-03-30
CA2284817A1 (en) 1998-10-01
EP0975973A1 (de) 2000-02-02

Similar Documents

Publication Publication Date Title
DE69833105D1 (de) Verfahren zur feststellung der anwesenheit mutierten brca proteins
DE69524182D1 (de) 17Q-Verbundenes Ovarial- und Brustkrebs Empfindlichkeitsgen
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
DE60041839D1 (de) Auto-Antikörper gegen Annexin-Proteine als Marker für Lungenkrebs
PL350318A1 (en) Protein isolation and analysis
DE59710933D1 (de) Messanordnung zur optischen Bestimmung der totalen Hämoglobinkonzentration
DE69521002D1 (de) Mutationen des mit 17q verbundenen Ovarial- und Brustkrebs Empfindlichkeitsgens
ATE322014T1 (de) Krebsnachweisverfahren und reagenzien
DE69903898D1 (de) Teststreifen zur visuellen Ermittlung der Blutglukose-Konzentration
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
IL71699A0 (en) Methods and kits for the analysis and detection of biological or genetic material
AU7571998A (en) Rapid evaluation of the ratio of biological molecules
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
DK0981644T3 (da) APC mutation, der står i forbindelse med familierelateret colorectal cancer hos Ashkenazi -jøder
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
DE69016858D1 (de) Verfahren und Reagenziensatz zur Bestimmung der funktionalen Aktivität von Protein S in menschlichem Plasma.
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
WO2000024768A3 (en) Genes integrating signal transduction pathways
EP1572931A4 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
DE69839846D1 (de) Bestimmung der vorhandenen mengen an cyclin-abhängr bei krebspatienten
DK1381696T3 (da) Methods
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
EP0950062A4 (de) Proteinmarker für ösophaguskrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties